The randomized controlled trial

Summary In an era in which all aspects of medicine are being driven by evidence, one consequence has been an increased use of randomized controlled trials. This is not surprising as they represent the most rigorous method of assessment as, by their very nature, they eliminate much of the potential bias that makes other means of comparing ‘treatments' less reliable. In order to produce clear evidence, however, any trial must be well constructed and carried out. Achieving this requires careful planning, and in this article we hope to cover the important issues that must be considered in relation to any randomized controlled trial.

[1]  J. Sloan,et al.  Decision making during serious illness: what role do patients really want to play? , 1992, Journal of clinical epidemiology.

[2]  D G Altman,et al.  Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. , 1994, JAMA.

[3]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[4]  M. Ardagh Futility has no utility in resuscitation medicine , 2000, Journal of medical ethics.

[5]  D. Zingmond,et al.  Regional and institutional variation in the initiation of early do-not-resuscitate orders. , 2005, Archives of internal medicine.

[6]  E. Bruera,et al.  Impact of physician sitting versus standing during inpatient oncology consultations: patients' preference and perception of compassion and duration. A randomized controlled trial. , 2005, Journal of pain and symptom management.

[7]  W. Haley,et al.  Current research findings on end-of-life decision making among racially or ethnically diverse groups. , 2005, The Gerontologist.

[8]  L. Heffner,et al.  Production of prolactin by smooth muscle cells cultured from human uterine fibroid tumors. , 1993, The Journal of clinical endocrinology and metabolism.

[9]  Douglas G Altman,et al.  How to randomise , 1999, BMJ.

[10]  M K Campbell,et al.  Extending the CONSORT statement to cluster randomized trials: for discussion. , 2001, Statistics in medicine.

[11]  D. Elbourne,et al.  Zelen randomization: attitudes of parents participating in a neonatal clinical trial. , 1998, Controlled clinical trials.

[12]  P. Muskin,et al.  Effects of religiosity on patients' perceptions of do-not-resuscitate status. , 2004, Psychosomatics.

[13]  B. Messinger-Rapport,et al.  Predictors of do not resuscitate orders in the nursing home. , 2005, Journal of the American Medical Directors Association.

[14]  J. Grizzle THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. , 1965, Biometrics.

[15]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[16]  N. Chabbert-Buffet,et al.  Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. , 2005, Human reproduction update.

[17]  P. Butow,et al.  Misunderstanding in cancer patients: why shoot the messenger? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Bruera,et al.  Patient preferences versus physician perceptions of treatment decisions in cancer care. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Wallston,et al.  The Development of a Brief Version of the Santa Clara Strength of Religious Faith Questionnaire , 2002 .

[20]  J. Curtis Communicating with patients and their families about advance care planning and end-of-life care. , 2000, Respiratory care.

[21]  K. Coyne,et al.  The UFS‐QOL, a New Disease‐Specific Symptom and Health‐Related Quality of Life Questionnaire for Leiomyomata , 2002, Obstetrics and gynecology.

[22]  Sylvie Chevret,et al.  Risk of post-traumatic stress symptoms in family members of intensive care unit patients. , 2005, American journal of respiratory and critical care medicine.

[23]  Kenneth F. Schulz,et al.  The CONSORT Statement , 1996 .

[24]  M. Merino,et al.  A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. , 2000, Human reproduction.

[25]  D. Elbourne,et al.  Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. , 1997, Social science & medicine.

[26]  P. Maguire,et al.  The relationship between patients' concerns and psychological distress in a hospice setting , 1998, Psycho-oncology.

[27]  W. Baile,et al.  Discussing disease progression and end-of-life decisions. , 1999, Oncology.

[28]  J. Steinauer,et al.  Systematic Review of Mifepristone for the Treatment of Uterine Leiomyomata , 2004, Obstetrics and gynecology.

[29]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[30]  M. Kenward,et al.  Design and Analysis of Cross-Over Trials , 1989 .

[31]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[32]  Duncan Macrae,et al.  UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation , 1996, The Lancet.

[33]  J. Ptacek,et al.  Breaking Bad News: A Review of the Literature , 1996 .

[34]  A. Patel,et al.  The frequency of uterine leiomyomas. , 1990, American journal of clinical pathology.

[35]  J. Reel,et al.  In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[36]  A. Sherman,et al.  Measuring religious faith in cancer patients: reliability and construct validity of the Santa Clara strength of religious faith questionnaire , 2001, Psycho-oncology.

[37]  A. Lethaby,et al.  Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. , 2000, The Cochrane database of systematic reviews.

[38]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .

[39]  K. Schulz,et al.  Subverting randomization in controlled trials. , 1995, JAMA.

[40]  R. Williams,et al.  Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. , 2002, Molecular human reproduction.

[41]  M. Somerfield,et al.  Can 40 seconds of compassion reduce patient anxiety? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Elbourne,et al.  Reactions of participants to the results of a randomised controlled trial: exploratory study , 1998, BMJ.

[43]  U. Haag Technologies for Automating Randomized Treatment Assignment in Clinical Trials , 1998 .

[44]  Douglas G. Altman,et al.  RANDOMISATION : ESSENTIAL FOR REDUCING BIAS , 1991 .

[45]  E. Bruera,et al.  Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. , 2000, Archives of internal medicine.

[46]  R. Kruse,et al.  Effect of Do‐Not‐Resuscitate Orders on Hospitalization of Nursing Home Residents Evaluated for Lower Respiratory Infections , 2004, Journal of the American Geriatrics Society.

[47]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[48]  D. Dixon,et al.  Etiology and pathogenesis of uterine leiomyomas: a review. , 2003, Environmental health perspectives.

[49]  Philip H. Ramsey Nonparametric Statistical Methods , 1974, Technometrics.

[50]  A. Fairchild,et al.  In pursuit of an artful death: discussion of resuscitation status on an inpatient radiation oncology service , 2005, Supportive Care in Cancer.

[51]  C. McPherson,et al.  Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials. , 2001, Journal of public health medicine.

[52]  V T Chang,et al.  Validation of the Edmonton Symptom Assessment Scale , 2000, Cancer.

[53]  R. Labianca,et al.  Edmonton symptom assessment scale: Italian validation in two palliative care settings , 2005, Supportive Care in Cancer.

[54]  C. Steiner,et al.  Hysterectomy Rates in the United States 1990–1997 , 2002, Obstetrics and gynecology.

[55]  A. Donner,et al.  Design and Analysis of Cluster Randomized Trials , 2001 .

[56]  G. Enas,et al.  Baseline Comparability in Clinical Trials: Prevention of “Poststudy Anxiety” , 1990 .

[57]  Neeraj Arora,et al.  Patient preferences for medical decision making: who really wants to participate? , 2000, Medical care.

[58]  L. Nieman,et al.  Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. , 2003, Human reproduction.

[59]  E. Bruera,et al.  The Edmonton staging system for cancer pain: preliminary report , 1989, Pain.